Last reviewed · How we verify

Ropivacaine, Ketorolac and Adrenaline

University of Aarhus · FDA-approved active Small molecule

Ropivacaine, Ketorolac and Adrenaline is a Local anesthetic combination with NSAID and vasopressor Small molecule drug developed by University of Aarhus. It is currently FDA-approved for Local infiltration anesthesia and perioperative pain management, Surgical site anesthesia with hemostasis.

This combination provides local anesthesia via sodium channel blockade (ropivacaine), pain relief through COX inhibition (ketorolac), and vasoconstriction with sympathomimetic effects (adrenaline).

This combination provides local anesthesia via sodium channel blockade (ropivacaine), pain relief through COX inhibition (ketorolac), and vasoconstriction with sympathomimetic effects (adrenaline). Used for Local infiltration anesthesia and perioperative pain management, Surgical site anesthesia with hemostasis.

At a glance

Generic nameRopivacaine, Ketorolac and Adrenaline
SponsorUniversity of Aarhus
Drug classLocal anesthetic combination with NSAID and vasopressor
TargetVoltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that blocks sodium channels in nerve membranes, preventing action potential propagation. Ketorolac is a non-selective NSAID that inhibits cyclooxygenase enzymes to reduce prostaglandin-mediated inflammation and pain. Adrenaline acts as a sympathomimetic agent causing vasoconstriction, which prolongs local anesthetic duration and reduces systemic absorption and bleeding.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ropivacaine, Ketorolac and Adrenaline

What is Ropivacaine, Ketorolac and Adrenaline?

Ropivacaine, Ketorolac and Adrenaline is a Local anesthetic combination with NSAID and vasopressor drug developed by University of Aarhus, indicated for Local infiltration anesthesia and perioperative pain management, Surgical site anesthesia with hemostasis.

How does Ropivacaine, Ketorolac and Adrenaline work?

This combination provides local anesthesia via sodium channel blockade (ropivacaine), pain relief through COX inhibition (ketorolac), and vasoconstriction with sympathomimetic effects (adrenaline).

What is Ropivacaine, Ketorolac and Adrenaline used for?

Ropivacaine, Ketorolac and Adrenaline is indicated for Local infiltration anesthesia and perioperative pain management, Surgical site anesthesia with hemostasis.

Who makes Ropivacaine, Ketorolac and Adrenaline?

Ropivacaine, Ketorolac and Adrenaline is developed and marketed by University of Aarhus (see full University of Aarhus pipeline at /company/university-of-aarhus).

What drug class is Ropivacaine, Ketorolac and Adrenaline in?

Ropivacaine, Ketorolac and Adrenaline belongs to the Local anesthetic combination with NSAID and vasopressor class. See all Local anesthetic combination with NSAID and vasopressor drugs at /class/local-anesthetic-combination-with-nsaid-and-vasopressor.

What development phase is Ropivacaine, Ketorolac and Adrenaline in?

Ropivacaine, Ketorolac and Adrenaline is FDA-approved (marketed).

What are the side effects of Ropivacaine, Ketorolac and Adrenaline?

Common side effects of Ropivacaine, Ketorolac and Adrenaline include Local tissue irritation or inflammation, Systemic toxicity from local anesthetic (CNS or cardiac), Gastrointestinal effects from ketorolac, Tachycardia or hypertension from adrenaline, Allergic reaction.

What does Ropivacaine, Ketorolac and Adrenaline target?

Ropivacaine, Ketorolac and Adrenaline targets Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac); alpha and beta adrenergic receptors (adrenaline) and is a Local anesthetic combination with NSAID and vasopressor.

Related